CENTRAL TRUST Co Cuts Stake in Bristol Myers Squibb Company $BMY

CENTRAL TRUST Co reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 112,648 shares of the biopharmaceutical company’s stock after selling 9,285 shares during the period. CENTRAL TRUST Co’s holdings in Bristol Myers Squibb were worth $5,080,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. lifted its stake in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the last quarter. Total Investment Management Inc. purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $40,000. Finally, Mark Sheptoff Financial Planning LLC increased its holdings in shares of Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BMY shares. Morgan Stanley restated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Leerink Partners increased their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Finally, Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $59.20.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $60.64 on Friday. The business has a 50 day moving average of $55.33 and a 200 day moving average of $49.44. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a market cap of $123.49 billion, a PE ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the firm posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.